Want to see TNGX full AI Analyst Report?
TNGX Stock Chart & Stats
$26.64
-$0.22(-6.34%)
At close: 4:00 PM EST
$26.64
-$0.22(-6.34%)
Day’s Range― - ―
52-Week Range$4.80 - $34.39
Previous CloseN/A
Volume187.94K
Average Volume (3M)4.65M
Market Cap
$5.09B
Enterprise Value$3.89B
Total Cash (Recent Filing)$379.84M
Total Debt (Recent Filing)$32.79M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 12, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding162,814,650
10 Day Avg. Volume8,047,518
30 Day Avg. Volume4,651,212
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue68.31
Enterprise Value/Gross Profit70.24
Enterprise Value/Ebitda-37.03
Forecast
1Y Price Target
$42.00Price Target Upside57.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.31
Revenue Forecast (FY)$6.06M
Bulls Say, Bears Say
Bulls Say
Extended Funding RunwayA large underwritten equity offering that yields multi-year funding materially reduces near-term financing risk and funds pivotal trials and commercialization prep. This durable capital cushion supports late-stage development timelines and strategic optionality without immediate dilution-driven pressure.
Low Leverage / Balance Sheet StrengthVery modest leverage and substantial equity provide financial flexibility for a clinical-stage biotech. Low debt lowers bankruptcy and interest-rate exposure, enabling the company to invest in R&D and absorb trial timing variability while accessing capital markets from a stronger balance-sheet position.
Promising Clinical Data For Lead AssetRobust early vopimetostat combination efficacy and tolerability that prompted prioritization to Phase 3 materially de-risks the lead program versus preclinical assets. If durable, this positions Tango as a potential leader in MTAP-deleted cancers and supports a clear development pathway toward commercialization.
Bears Say
High Cash BurnSustained large negative operating and free cash flows reflect heavy R&D and trial spend, meaning the company depends on external financing over the medium term. Prolonged burn can force dilutive raises or constrain program pacing if trial timelines slip or milestones are delayed.
Substantial Operating LossesMaterial operating and net losses, despite strong gross margins, indicate business economics dominated by development expenses. This limits near-term earnings visibility and places long-term investor returns squarely on successful clinical outcomes and eventual commercialization of lead assets.
Revenue Decline & Milestone-Driven ModelDeclining trailing revenue and reliance on collaboration/licensing payments create lumpy, milestone-based cash inflows. Without approved products, revenue lacks diversification and predictability, increasing operational risk if partner-funded programs or milestone timing change.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics, Inc.’s price range in the past 12 months?
Tango Therapeutics, Inc. lowest stock price was $4.80 and its highest was $34.39 in the past 12 months.
What is Tango Therapeutics, Inc.’s market cap?
Tango Therapeutics, Inc.’s market cap is $5.09B.
When is Tango Therapeutics, Inc.’s upcoming earnings report date?
Tango Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Tango Therapeutics, Inc.’s earnings last quarter?
Tango Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.314 by -$0.006.
Is Tango Therapeutics, Inc. overvalued?
According to Wall Street analysts Tango Therapeutics, Inc.’s price is currently Undervalued.
Does Tango Therapeutics, Inc. pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
What is Tango Therapeutics, Inc.’s EPS estimate?
Tango Therapeutics, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Tango Therapeutics, Inc. have?
Tango Therapeutics, Inc. has 162,814,650 shares outstanding.
What happened to Tango Therapeutics, Inc.’s price movement after its last earnings report?
Tango Therapeutics, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.314. Following the earnings report the stock price went down -2.509%.
Which hedge fund is a major shareholder of Tango Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (57.66% Upside)
$42.00 (57.66% Upside)
Blogger Sentiment
Bearish
TNGX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $241.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 31.7%
Last 30 Days ▲ 31.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
549.90%
12-Months-Change
Fundamentals
Return on Equity
-41.54%
Trailing 12-Months
Asset Growth
58.87%
Trailing 12-Months
Company Description
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$42.00
▲(57.66% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
10.98% Insiders
8.10% Mutual Funds
10.88% Other Institutional Investors
58.97% Public Companies and Individual Investors